Laurence Lasky - 06 Oct 2021 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 06 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Oct 2021, 17:12:48 UTC
Prior SEC filing: 27 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Michael Byrnes, Attorney-in-Fact for Laurence Lasky

Key filing fact

Laurence Lasky filed Form 4 for eFFECTOR Therapeutics, Inc. on 08 Oct 2021.

Key facts

This page summarizes Laurence Lasky's Form 4 filing for eFFECTOR Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Oct 2021, 17:12.

Change

Previous filing in this sequence was filed on 27 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EFTR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 06 Oct 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $11.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Reporting Person's continued service with the Issuer through each vesting date.